Literature DB >> 2162366

Antigen presentation and T-cell activation in epidermodysplasia verruciformis.

K D Cooper1, E J Androphy, D Lowy, S I Katz.   

Abstract

Aberrant immune responses may play a role in the susceptibility of patients with epidermodysplasia verruciformis to human papilloma virus (HPV). We examined the stimulatory capacity of antigen-presenting cells from HPV-infected skin and peripheral blood T-cell responses of patients with epidermodysplasia verruciformis. The percentage of Langerhans cells in relation to total epidermal cells in suspension was slightly reduced in HPV-infected lesions, relative to apparently clinically uninfected epidermis. In addition, the morphologic appearance of Langerhans cells was altered in lesional epidermal sheets. Despite these abnormalities, Langerhans cells were functionally intact in their capacity to present alloantigens to T cells and, in fact, the epidermis of HPV-infected lesions demonstrated enhanced antigen-presenting activity in three of four patients tested. The antigen-presenting activity was entirely abrogated by removal of Langerhans cells and was not associated with increased activity of cytokines with stimulatory activity for the thymocyte co-stimulation assay. Although epidermodysplasia verruciformis T cells were unresponsive to autologous HPV-infected epidermis, they responded well to mitogens, allogeneic mononuclear leukocytes, and allogeneic epidermal cells. Epidermodysplasia verruciformis T cells were inhibited in their capacity to respond to allogeneic epidermal cells when they were simultaneously exposed to autologous epidermal cells from HPV-infected lesional epidermis, but not to normal-appearing epidermis. Thus, although Langerhans cell activity is intact in epidermodysplasia verruciformis, these individuals fail to respond to autologous papillomas, which may, at least in part, be explained by an interaction between papillomal epidermal cells and autologous T cells that results in an inhibited response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162366     DOI: 10.1111/1523-1747.ep12874631

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.

Authors:  N D Christensen; R Han; N M Cladel; M D Pickel
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 3.  Human papillomavirus and the development of non-melanoma skin cancer.

Authors:  C A Harwood; J M McGregor; C M Proby; J Breuer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

5.  Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses.

Authors:  Sarah J de Jong; Elias Imahorn; Peter Itin; Jouni Uitto; Gérard Orth; Emmanuelle Jouanguy; Jean-Laurent Casanova; Bettina Burger
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

6.  Human papillomavirus type 8 interferes with a novel C/EBPβ-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration.

Authors:  Tanya Sperling; Monika Ołdak; Barbara Walch-Rückheim; Claudia Wickenhauser; John Doorbar; Herbert Pfister; Magdalena Malejczyk; Sławomir Majewski; Andrew C Keates; Sigrun Smola
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

7.  The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.

Authors:  Jaime S Horton; Alexander J Stokes
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.